Answers are grounded in this paper and cite their sources.
According to the latest study published by the EADV, nearly 3 million European adults are affected by Hidradenitis suppurativa (HS), making it 1 of the 12 most common skin diseases.1 There are two main types of sleep disorder reported: sleep onset insomnia (difficulty falling asleep) (SOI) and sleep maintenance insomnia (characterised by night-time awakenings) (SMI),2 In a recent study, ‘sleep disorders’ (SD) were found to be common in patients with HS.3 However the relationship between HS and these two different sleep disorders has never been specifically studied. The objective of this study was to estimate the prevalence of SOI and SMI and their associated clinical factors as well as fatigue in patients with HS. For this observational and cross-sectional study, a digital questionnaire was distributed by the two patient association co-authors of this paper to a population of patients over 18 years of age suffering from HS confirmed by a physician. The questionnaire included sociodemographic characteristics and Patient's Global Assessment of the disease (mild, moderate or severe); the presence of itching, burning and pain related to HS in the last 7 days were also assessed. Quality of life (measured by the Dermatology Life Quality Index, DLQI),4 and sleep quality were administered to assess the presence of SOI and SMI. SOI was assessed in case of a positive answer to the question: In the last 7 days, did you ever take more than 20 min to fall asleep? SMI was assessed in case of a positive answer to the question: In the last 7 days, have you ever woken up at night and had difficulty falling back asleep? Feeling of fatigue sensation was assessed in case of positive answer to the question ‘After a normal night's sleep, how do you feel?’ A chi-square test and Fisher's exact test were performed. A value less than 0.05 was considered statistically significant. There were 524 study participants (85.6% women, average age ± SD = 36.9 ± 9.9 years). A total of 62 (11.8%) had mild, 278 (53.1%) moderate and 184 (35.1%) severe HS. 353 (77.6%) had DLQI ≥10, 480 (91.6%) had skin symptoms (pruritus, skin pain and burning sensation), and 466 (88.9%) had feeling of fatigue. In our study, 86.3% of patients with HS complained of sleep disorders. The prevalence of sleep disorders, SOI and SMI, in different subgroups of patients, are displayed in Table 1 and Figure 1. A total of 55.2% of patients reported sleeping less than 6 h per night at least three times per week. SMI was more prevalent than SOI as sleep disorder but most patients complained of both. On the one hand, compared to patients with SMI alone, patients with SOI alone or both SOI and SMI more frequently suffered from: sleep duration of less than 6 h per night at least three times per week and feeling of fatigue, moderate and severe forms of HS, significant impairment of quality of life (DLQI ≥ 10) and pain related to active skin lesions (Table 1). This information should be put into perspective with the results of a recent study, using modern means and evaluating the average duration of sleep using smartphone data. The French had an average sleep duration of 8 h 3 min.5 On the other hand, there is no difference of feeling of fatigue and pain related to active lesions of HS between patients with HS suffering from SMI alone and SOI alone. It is worth remembering that HS is not the only skin condition to cause sleep problems. A recent international study involving more than 2800 people compared people with skin disease (acne, atopic dermatitis, psoriasis and chronic hand eczema) to a population without skin disease.6 This study revealed a significantly higher prevalence of sleep disorders in patients with skin disease (71.2% vs. 32.7% in the control group of patients, p: <0.001). A systematic review of HS and sleep disorders and sleep quality in patients with HS has recently been published. It has the merit of having studied data from seven studies involving more than 380,000 individuals. This work confirms that patients reported poorer quality sleep due to HS symptoms such as pruritus and pain.7 This is the first epidemiological study to evaluate the prevalence of different types of insomnia in patients with HS. This study suggests that sleep disturbances weigh heavily on adults with HS, especially in patients with moderate and severe forms, DLQI ≥ 10 and pain. Treatments targeting sleep loss, as well as effective treatment of the HS disease itself, are likely to improve the overall health of HS patients. Charles Taieb, Bruno Halioua, Marie Aleth Richard and Jonathan Taieb contributed to the methodology, the realisation of the evaluation, the statistical analysis and the writing of the publication. Yaron Ben Hayoun contributed to the statistical analysis. Marie France Bru and Helene Raynal contributed to the construction of the administered questionnaire, questionnaire distribution and the writing of the publication. The authors would like to thank the patients and their associations who made the project possible. This study was funded by le Printemps des Maladies Inflammatoires Chroniques de la Peau. The authors declare no conflict of interest. A favourable opinion was obtained from CPP IDF11—Ile-de-France XI. The data supporting the findings of this paper is available from the corresponding author upon reasonable request.
No takes yet. Share an insight, caveat, or question.
Halioua et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: